Capricor Therapeutics, Inc. (CAPR) stock
CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.03−0.38 (-4.52%)
Close on Nov 18, 2026Market cap $466.86MP/E –Yield –
Capricor Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Capricor Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $22.27M, down 11.5% year over year. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $25.18M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $22.27M | -11.5% |
| FY2023 | Dec 31, 2023 | $25.18M | +886.8% |
| FY2022 | Dec 31, 2022 | $2.55M | +941.8% |
| FY2021 | Dec 31, 2021 | $244.90K | -21.1% |
| FY2020 | Dec 31, 2020 | $310.25K | -69.1% |
| FY2019 | Dec 31, 2019 | $1.01M | -39.9% |
| FY2018 | Dec 31, 2018 | $1.67M | -37.3% |
| FY2017 | Dec 31, 2017 | $2.67M | -33.3% |
| FY2016 | Dec 31, 2016 | $4.00M | -27.5% |
| FY2015 | Dec 31, 2015 | $5.52M | +15.3% |
| FY2014 | Dec 31, 2014 | $4.79M | +851.2% |
| FY2013 | Dec 31, 2013 | $503.23K | +157.4% |
| FY2012 | Dec 31, 2012 | $195.50K | -85.6% |
| FY2011 | Dec 31, 2011 | $1.35M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $11.13M | -7.9% |
| Q3 FY2024 | Sep 30, 2024 | $2.26M | -63.4% |
| Q2 FY2024 | Jun 30, 2024 | $3.97M | +1.4% |
| Q1 FY2024 | Mar 31, 2024 | $4.91M | +64.3% |
| Q4 FY2023 | Dec 31, 2023 | $12.09M | +1159.3% |
| Q3 FY2023 | Sep 30, 2023 | $6.19M | +288.7% |
| Q2 FY2023 | Jun 30, 2023 | $3.92M | – |
| Q1 FY2023 | Mar 31, 2023 | $2.99M | – |
| Q4 FY2022 | Dec 31, 2022 | $959.90K | +370.4% |
| Q3 FY2022 | Sep 30, 2022 | $1.59M | +3799.4% |
| Q4 FY2021 | Dec 31, 2021 | $0 | -100.0% |
| Q3 FY2021 | Sep 30, 2021 | $0 | -100.0% |
| Q2 FY2021 | Jun 30, 2021 | $204.08K | +309.3% |
| Q1 FY2021 | Mar 31, 2021 | $40.82K | -78.0% |
| Q4 FY2020 | Dec 31, 2020 | $57.83K | -74.0% |
| Q3 FY2020 | Sep 30, 2020 | $16.86K | -88.1% |
| Q2 FY2020 | Jun 30, 2020 | $49.86K | -87.8% |
| Q1 FY2020 | Mar 31, 2020 | $185.69K | -19.4% |
| Q4 FY2019 | Dec 31, 2019 | $222.10K | -65.7% |
| Q3 FY2019 | Sep 30, 2019 | $142.07K | -35.2% |
| Q2 FY2019 | Jun 30, 2019 | $410.35K | +1.6% |
| Q1 FY2019 | Mar 31, 2019 | $230.50K | -42.4% |
| Q4 FY2018 | Dec 31, 2018 | $648.08K | +36.2% |
| Q3 FY2018 | Sep 30, 2018 | $219.25K | -30.0% |
| Q2 FY2018 | Jun 30, 2018 | $403.96K | -59.5% |
| Q1 FY2018 | Mar 31, 2018 | $400.07K | -54.6% |
| Q4 FY2017 | Dec 31, 2017 | $475.80K | -47.5% |
| Q3 FY2017 | Sep 30, 2017 | $313.27K | -58.1% |
| Q2 FY2017 | Jun 30, 2017 | $996.46K | – |
| Q1 FY2017 | Mar 31, 2017 | $880.81K | – |
| Q4 FY2016 | Dec 31, 2016 | $906.93K | – |
| Q3 FY2016 | Sep 30, 2016 | $746.78K | – |
See a number that looks wrong?